These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 21767763

  • 1. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S, Naugolny V, Korbut Z, Rozen I, Caspi A, Malnick S.
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [Abstract] [Full Text] [Related]

  • 2. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB, Rao K, Sawyer R, Gottlieb SS.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):845-9. PubMed ID: 16139135
    [Abstract] [Full Text] [Related]

  • 3. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP, Aaronson KD, Koelling TM.
    Am Heart J; 2004 Dec 06; 148(6):971-8. PubMed ID: 15632880
    [Abstract] [Full Text] [Related]

  • 4. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 06; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 5. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S, Maeder MT, Toggweiler S, Rickli H, Nietlispach F, Julius B, Burkard T, Pfisterer ME, Brunner-La Rocca HP, TIME-CHF Investigators.
    Am J Cardiol; 2012 Mar 01; 109(5):693-8. PubMed ID: 22152974
    [Abstract] [Full Text] [Related]

  • 6. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
    N Engl J Med; 1999 Sep 02; 341(10):709-17. PubMed ID: 10471456
    [Abstract] [Full Text] [Related]

  • 7. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS, Cruz LS, Domingues GS, Souza CA.
    Expert Opin Drug Saf; 2005 Jul 02; 4(4):677-88. PubMed ID: 16011447
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
    Witham MD, Gillespie ND, Struthers AD.
    Br J Clin Pharmacol; 2004 Nov 02; 58(5):554-7. PubMed ID: 15521905
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W, McAlister FA, Ezekowitz J, Armstrong PW.
    Am J Cardiol; 2004 Aug 15; 94(4):443-7. PubMed ID: 15325926
    [Abstract] [Full Text] [Related]

  • 11. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
    Matsumura T, Saito T, Miyai I, Nozaki S, Kang J.
    Rinsho Shinkeigaku; 2000 May 15; 40(5):439-45. PubMed ID: 11002725
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [An elderly man with known heart failure admitted with cardiogenic shock].
    Hovland A, Fagerheim AK, Hardersen R, Nielsen EW.
    Tidsskr Nor Laegeforen; 2010 Jul 01; 130(13):1352-4. PubMed ID: 20596117
    [Abstract] [Full Text] [Related]

  • 15. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT, Juurlink DN, Mamdani MM, You JJ, Wang JT, Donovan LR, Tu JV.
    J Card Fail; 2006 Apr 01; 12(3):205-10. PubMed ID: 16624686
    [Abstract] [Full Text] [Related]

  • 16. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D, Frey FJ, Ferrari P.
    Praxis (Bern 1994); 2000 Dec 07; 89(49):2073-6. PubMed ID: 11190849
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD, Rockwell JE, Fallaw TK, Calvert CA.
    J Vet Cardiol; 2007 Nov 07; 9(2):103-8. PubMed ID: 17983885
    [Abstract] [Full Text] [Related]

  • 19. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S.
    Am Heart J; 2003 Mar 07; 145(3):459-66. PubMed ID: 12660669
    [Abstract] [Full Text] [Related]

  • 20. Clinical factors associated with hyperkalemia in patients with congestive heart failure.
    Ramadan FH, Masoodi N, El-Solh AA.
    J Clin Pharm Ther; 2005 Jun 07; 30(3):233-9. PubMed ID: 15896240
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.